Private Capital Advisors Inc. Sells 47,837 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Private Capital Advisors Inc. lessened its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 86.7% in the 4th quarter, Holdings Channel reports. The firm owned 7,348 shares of the company’s stock after selling 47,837 shares during the period. Private Capital Advisors Inc.’s holdings in Structure Therapeutics were worth $511,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. State of Wyoming bought a new stake in shares of Structure Therapeutics during the second quarter worth $28,000. EverSource Wealth Advisors LLC increased its position in shares of Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares in the last quarter. CWM LLC increased its position in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,146 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Structure Therapeutics during the second quarter worth $129,000. Institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright lowered their price objective on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 16th. Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Finally, Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Structure Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $109.25.

Structure Therapeutics Trading Up 1.0%

Shares of GPCR opened at $39.19 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $15.80 and a 12 month high of $94.90. The firm has a fifty day simple moving average of $46.77 and a 200 day simple moving average of $56.65. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -45.05 and a beta of -1.31.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.29 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.